BLOG AND WHITEPAPERS
Recon takes an analytical look behind select developments in healthcare
Keep up with the Recon Strategy Insights
Get an email each time Recon takes an analytical look behind select developments in healthcare.
Search
- By Marc Herant
Genetic trade secrets
In 2012, the US Supreme Court decided a case known as “Prometheus” establishing that therapeutic methods based on biomarkers were not patentable – this essentially blocked one of…
- By Marc Herant
Peanut medicine that won’t cost peanuts
Allergy to peanuts is a major issue and though prevention is now possible in infants there is a huge population for whom actual survival is connected to vigilan…
- By Tess Niewood
Interest and investment in digital health has increased rapidly in recent years. Some digital health software is impactful enough that it requires FDA approval, but current regulatory pathways are sl…
- By Marc Herant
One century after the use of convalescent serum, convalescent T-cells
The use of tailored T-cells (e.g. CAR-T) is transforming our approach to (blood) cancers, but what about using T-cells against the…
- By Marc Herant
Primary care organizations are better ACOs when it comes to achieving savings
Initial results from the Medicare Shared Savings Program ACO have been disappointing pointing to small to negligible net e…
- By Marc Herant
Transthyretin heats up
Last month saw a couple landmark papers about the use of parenteral RNA drugs (from Alnylam and Ionis) in hereditary transthyretin amyloidosis with a focus mainly on mitigating …
- By Marc Herant
RNA drugs coming of age
Hereditary Transthyretin Amyloidosis (ATTR) is a genetic disease in which one of the alleles of Transthyretin (TTR), a protein produced by the liver and with a role in thyroid …
- By Marc Herant
It’s hard to quit (and E-cigs don’t help)
A large trial (6000 participants) comparing free cessation support, e-cigarettes, and a $600 cash incentive for sustained abstinence shows that none of these …